Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Emisphere Development Update | ||
By: Nasdaq / GlobeNewswire - 21 Jun 2018 | Back to overview list |
|
ROSELAND, N.J., June 21, 2018 (GLOBE NEWSWIRE) -- Novo Nordisk announced yesterday the completion and results of the phase 3a trials, PIONEER 4 and 7, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilizes Emisphere Technologies, Inc.'s ("Emisphere" or the "Company") (OTCBB:EMIS) proprietary Eligen® Technology. A copy of the Novo Nordisk's announcement can be found at: https://www.novonordisk.com/media/news-details.2200408.html About Emisphere This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to the Company's development activities and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the Company's business development activities. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including, but not limited to, the sufficiency of Emisphere's cash position, the success of our and our partner's development and commercialization efforts, and our ability to successfully partner our Eligen® Technology. CONTACT:
|
||
|
||
Copyright 2018 Nasdaq / GlobeNewswire | Back to overview list |